One limitation from the study herein might be that it does not address whether the dual-specific compound acazicolcept may offer a benefit as compared to single therapies targeting CD28 or ICOS alone; however, each single therapy has already demonstrated its relevance in SSc [28, 29, 40, 43] and in other CTDs [52–59]. This evidence concerns the gene CD28 and systemic sclerosis.